All patients underwent successful CRT-P (pacemaker only CRT) or CRT-D (CRT with implantable cardioverter defibrillator) implantation. The right atrial and right ventricular leads were positioned in the right appendage and mid interventricular septum or in the RV apex. Left ventricular lead positioning was performed under guidance of venography, and when accessible lateral or postero-lateral cardiac veins were chosen. Implanted devices included Contak Renewal (Guidant Corp., Arden Hills, MN, USA), Cognis (Boston Scientific USA), Stratos, Lumax (Biotronik, Berlin, Germany) and Insync III (Medtronic Inc., Minneapolis, MN, USA). We implanted CRT-Ds to 46% of the patients. CRT-D was indicated in case of those patients who suffered previously documented ventricular arrhythmias and whenever it was indicated by the referring physician [14 (link)].
Cognis
Manufactured by Boston Scientific
Sourced in United States, New Zealand
Cognis is a laboratory equipment product designed to perform advanced signal processing and waveform analysis. It is a versatile tool that captures, processes, and analyzes complex signals across various applications.
Automatically generated - may contain errors
Lab products found in correlation
4 protocols using cognis
1
Cardiac Resynchronization Therapy Implantation
2
Cardiac Resynchronization Therapy Implantation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Cardiac resynchronization therapy was implanted successfully in all patients without major complications. The right atrial (where appropriate) and right ventricular (RV) leads were positioned in the right appendage and mid-interventricular septum or in the RV apex, respectively. Coronary sinus venography was used for LV lead positioning. Lateral and posterolateral cardiac veins were preferred for LV lead implantation. Implanted devices were Contak Renewal (Guidant Corp., Arden Hills, MN, USA). Cognis (Boston Scientific, Marlborough, MA, USA), Stratos, Lumax (Biotronik, Berlin, Germany), and Insync III (Medtronic Inc., Minneapolis, MN, USA).
3
Cardiac Dysfunction Impact on HS
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Two unique animal models were used to evaluate the impact of worsening cardiac function on HS, namely, an acute ischaemia induction to model the contractility changes in HF and an acute pulmonary oedema induction to model congestion in HF. The two models were implemented separately in distinct sets of animals. All animals were acutely implanted with three transvenous leads and a cardiac resynchronization therapy defibrillator (CRT‐D) device (COGNIS®, Boston Scientific, Marlborough, MA) modified via a software download to enable recording and storing HS data from the embedded accelerometer. Both studies were approved by the Boston Scientific Corporation Institutional Animal Care and Use Committee and carried out at an American Association for the Accreditation of Laboratory Animal Care facility in compliance with regulations set forth in the Animal Welfare Act, Title 9, CFR, Chapter 1, Subchapter A and principles outlined in the ‘Guide for the Care and Use of Animals’, by National Research Council.
4
Wearable Sensors for Early Heart Failure Detection
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The MultiSENSE study has been previously published (ClinicalTrials.gov Identifier: NCT01128166).9 In brief, MultiSENSE is an international, multicentre, non‐randomized study designed to develop and evaluate a multi‐sensor based algorithm for the early detection of worsening heart failure. To be enrolled, patients were required to be implanted with an existing COGNIS™ cardiac resynchronization therapy defibrillator (CRT‐D) (Boston Scientific, Marlborough, MA). Following enrolment, patient demographics and clinical status were collected, and the patient's CRT‐D had custom research firmware installed on the device converting it to a Sensor Research Device. Scheduled follow‐ups occurred every 3 months if the patient had remote monitoring, otherwise patient follow‐up occurred every 6–8 weeks to allow for sensor data download. Patients were followed for up to 12 months, at the end of which their device was reconverted to the market approved COGNIS firmware. All patients provided written informed consent. The study was conducted in accordance with the ethical standards of the institutional and national research committees and with the 1964 Declaration of Helsinki and its later amendments.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!